Navigation Links
Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
Date:2/4/2013

Norwood, MA (PRWEB) February 04, 2013

Infinata’s BioPharm Insight™ capped another year of global expansion in 2012. BioPharm Insight offers subscribers the unique combination of comprehensive market analytics, a database of key industry contacts and proprietary forward-looking intelligence uncovered by an independent team of investigative journalists.

Ruth McHenry, Managing Director of Infinata, said, “BioPharm Insight continues its aggressive growth to meet the needs of industry professionals. Every day we work closely with our customers to understand and solve the challenges they face. I am so proud to say that in 2012 we met and exceeded all targeted areas of growth.”

New Features & Functionalities

New User Interface – BioPharm Insight’s completely redesigned user interface (UI) features a customizable homepage, easier navigation, and interactive charts and graphs. These enhancements allow subscribers to filter data and intelligence to fit their needs, allowing them to identify business opportunities as soon as they arise.

Increased Scope of Data – In addition to a new UI, BioPharm Insight continued to improve the scope of data provided to subscribers with the addition of:

  •     SEC filings
  •     NIH grant data
  •     Medicaid data
  •     EudraCT studies (BioPharm Clinical™)
  •     Expected Catalysts Calendar – by compiling study start and end dates, patent expirations and commercial launches by forecasts, BioPharm Insight provides the most comprehensive calendar of upcoming catalysts.

Analytics – Last year BioPharm Insight added the following analytics to further improve subscribers’ ability to find and use data quickly and efficiently:

  •     CRO activity
    '/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
4. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
5. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
6. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
7. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
8. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Angeles, California (PRWEB) October 23, 2014 ... ), a specialty pharmaceutical company devoted to bringing ... out-licensing partnerships in 2015. , ViaDerma has developed ... which allows for rapid mass transfer of pharmaceutical ... the body to provide immediate localized therapy. The ...
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... the development of oral drug delivery systems, announced today ... present at FireRock Capital,s Micro-Cap Conference. ... Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: The ... , About The FireRock Conference  ...
(Date:10/25/2014)... October 24, 2014 ... ) has announced the addition of the  ... And Other 2-D Nanomaterials "  report to ... , ,CNTs and graphene are the strongest, ... man, with a performance-per-weight greater than any ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
... SAN DIEGO, March 29, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... inhibitor program has been accepted for a late-breaking poster ... Annual Meeting on Monday, April 4, 2011 at 1:00 ...
... EXTON, Pa., March 29, 2011 Morphotek®, Inc., ... it has entered into a collaboration and license ... the parties will collaborate to develop and commercialize ... monoclonal antibody to specifically detect human folate receptor ...
... DIEGO, March 29, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the American College of Cardiology (ACC) ... ACC:  Ernest N. Morial Convention Center (Expo Hall), New ...
Cached Biology Technology:Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 2Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... Gene scanning techniques developed by Professor Ian Day and ... have a major impact on healthcare in the future. ... by Professor Day and his team in the Human ... been successfully applied to search for rare genetic mutations ...
... volume says Dutch researcher Bas Tomassen. He investigated the uptake ... and human cells. , Cell volume is the outcome ... the cell plasma membrane. A cell can regulate its volume ... Exactly how this process works is still not known. Bas ...
... Scientists at the Albert Einstein College of Medicine have ... causes tuberculosis may soon be able to resist the ... why several disease-causing microbes, including Shigella and E. coli, ... research effort was led by Dr. John S. Blanchard, ...
Cached Biology News:New gene scanning technology marks a major advance in disease research 2Water management in cells 2Einstein researchers identify new way that bacteria develop resistance to antibiotics 2
... 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: Heat ... phenol treatment followed by ethanol precipitation. Storage ... 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, 50% ... ice. Store at -20C. Unit Definition: One ...
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... Plus DNA Polymerase with a proprietary thermostable ... fidelity than standard Taq DNA polymerase, Double ... Amplifies DNA templates >20kb, Concentration: 5U/ul, Applications: ... cloning and mutagenesis We are part of ...
Biology Products: